LogiPharma's Charleen Ring and McKesson's Chris Van Norman preview the 2026 agenda, sessions to prioritize and a day two fireside chat.
|Podcasts|December 1, 2021
Navigating New State Drug Price Transparency Laws
Author(s)Model N
As the State Drug Pricing Transparency Program expands, what does that mean for manufacturers? Jesse Mendelsohn, Vice President, Centers of Excellence for Model N, the leader in cloud revenue management solutions for life science companies, discusses challenges for manufacturers as the State Price Transparency Program expands how they should plan for this change and the solutions they will need.
Advertisement
Advertisement
Related to this article
Cardinal Health and McKesson moved to extend CVS Health distribution deals through June 2032, retaining their largest customer pending final contracts.
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Mike Hennessy Jr. on the commercial assumptions being rewritten across pricing, patient engagement and supply chain in PC's October 2026 print issue.
In this Q&A, Doceree CEO Harshit Jain, MD, explains why AI should inform prescribing decisions, not drive them, and how sales reps own relationships while AI extends reach.
Patient support data that is trusted, connected and delivered into field workflows can move access teams from reporting to faster patient intervention.
In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
GLP-1 demand is straining pharma cold chain capacity, from tighter temperature thresholds and rising load rejections to fuel costs and trailer backlogs.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
2
What to Watch at LogiPharma: Resilience, Practical AI and New Peer Formats
3
Doceree CEO: AI Should Extend the Field Force, Not Replace It
4
Why Waltz Health, Fresenius Kabi Are Taking Biosimilars Direct
5